- Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-ThalassemiaZheng, Biao; Liu, Rongrong; Zhang, Xinhua; Fu, Bin; Xu, Yajing; Shi, Jun; Feng, Xiaoqin; Wang, Li; Wang, Chris; Liang, Rongmei; Tan, Lingzhi; Wang, Fei; Li, Dali; Wu, Yuxuan; Liu, Mingyao; Lai, Yongrong65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Therapeutic genome editing of an aberrant splice site in β-thalassemia by CRISPR/Cas9 with multiple sgRNAsYang, Fei; Xu, Shuqian; Huang, Chao; Shao, Zhiqiang; Hu, Yuefen; Yang, Yang; Lai, Yongrong; Ke, Qing; Liang, Dan*; Wu, Yuxuan*Genes & Diseases, 2024, 11(1): 15-18.
- Prime Editing of the α-Thalassemia Hb Constant Spring MutationShao, Congwen; Liu, Qing; Xu, Jinchao; Xin, Ye; Zhang, Jianxiang; Ye, Yuhua; Luo, Hualei; Zhang, Xinhua; Xu, Xiangmin; Xu, Peng65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
An Updated Follow-Up of BRL-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer for Transfusion-Dependent β-thalassemia
6阅读
